The lawsuit centers on claims that ARS Pharmaceuticals provided overly optimistic projections concerning the expansion of CVS Caremark insurance coverage for its key product, neffy. Defendants allegedly assured investors that coverage would commence on July 1, 2026, in time for peak allergy seasons, while simultaneously concealing material facts about the actual timeline. These disclosures reportedly led to artificially inflated stock prices, resulting in financial losses for shareholders when the information was corrected.

Rosen Law Firm, which is currently managing the case, states that investors seeking to participate in the class action may do so through a contingency fee arrangement, requiring no out-of-pocket costs. While a lawsuit has already been filed, no class has yet been certified. Investors retain the right to select their own counsel or remain absent class members, as the ability to participate in potential future recoveries is not strictly dependent on acting as a lead plaintiff.